Phosphodiesterases type 2, 3 and 4 promote vascular tone in mesenteric arteries from rats with heart failure

Liting Wang1, Fabien Hubert1, Sarah Idres1

  • 1Université Paris-Saclay, Inserm, UMR-S 1180, Orsay, France.

Insights

In heart failure (HF), phosphodiesterase (PDE) 3 and 4 contribute to vasoconstriction in mesenteric arteries, unlike in the aorta. PDE2 also promotes contraction, a role preserved in HF.

Area of Science:

  • Vascular Biology
  • Cardiovascular Physiology
  • Pharmacology

Background:

  • Phosphodiesterases (PDE) types 3 and 4 hydrolyze cyclic adenosine monophosphate (cAMP), promoting vasoconstriction.
  • In experimental heart failure (HF), PDE3's role in the aorta may render PDE4 redundant.
  • The roles of PDE2, PDE3, and PDE4 in resistance vessels like mesenteric arteries during HF are not well understood.

Purpose of the Study:

  • To investigate the function of PDE2, PDE3, and PDE4 in rat mesenteric arteries during experimental heart failure (HF).
  • To determine the contribution of these PDE isoenzymes to vasoconstriction and vasodilation in both healthy and failing conditions.

Main Methods:

  • Isolation of mesenteric arteries from rats with surgically induced HF or sham surgery.
  • Utilized PDE inhibitors in enzymatic and isometric tension assays.
  • Investigated the role of nitric oxide synthase (NOS) inhibition using L-NAME.

Main Results:

  • In healthy arteries, PDE2 and PDE4, but not PDE3, facilitated contraction.
  • In HF arteries, PDE2, PDE3, and PDE4 all contributed to contraction.
  • PDE3 and PDE4 activities were reduced in HF mesenteric arteries, while PDE2 activity remained.
  • PDE2 inhibition's effect was abolished by L-NAME, suggesting a link to NO synthase.
  • PDE3 and PDE4 attenuated beta-adrenergic relaxation in both healthy and HF states.

Conclusions:

  • Contrary to aortic findings, PDE3 and PDE4 equally contribute to mesenteric artery contraction in HF.
  • PDE2 activity promotes contraction and is preserved in the context of HF.
  • PDE2's role in contraction is linked to nitric oxide synthase activity.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
20
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
216
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
481
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
595
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
412